Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Applied Genetic Technologies Corp (AGTC) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Applied Genetic Technologies Corp. Table 2 shows the detailed insider transactions. This company's CIK number is 1273636.
Total stock buying since 2014: $203,294.
Total stock sales since 2014: $12,837,904.
Total stock option exercises since 2014: $180,843.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 0 | $0 | 22,014 | $31,319 | 120,686 | $42,240 |
| 2021 | 0 | $0 | 0 | $0 | 3,877 | $13,569 |
| 2019 | 2,544 | $7,097 | 81,162 | $425,288 | 37,718 | $31,156 |
| 2018 | 12,380 | $40,772 | 3,000 | $10,053 | 0 | $0 |
| 2016 | 17,400 | $155,425 | 1,000 | $7,052 | 12,328 | $39,998 |
| 2015 | 0 | $0 | 505,146 | $11,119,503 | 1,996 | $9,780 |
| 2014 | 0 | $0 | 59,000 | $1,244,689 | 9,000 | $44,100 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-07 | 0 | $0 | 8,070 | $6,254 | 0 | $0 |
| 2022-05 | 0 | $0 | 3,994 | $3,374 | 0 | $0 |
| 2022-02 | 0 | $0 | 9,950 | $21,691 | 120,686 | $42,240 |
| 2021-11 | 0 | $0 | 0 | $0 | 3,877 | $13,569 |
| 2019-12 | 0 | $0 | 81,162 | $425,288 | 0 | $0 |
| 2019-11 | 2,544 | $7,097 | 0 | $0 | 0 | $0 |
| 2019-09 | 0 | $0 | 0 | $0 | 5,700 | $19,950 |
| 2019-05 | 0 | $0 | 0 | $0 | 32,018 | $11,206 |
| 2018-12 | 12,380 | $40,772 | 3,000 | $10,053 | 0 | $0 |
| 2016-11 | 3,000 | $28,875 | 1,000 | $7,052 | 0 | $0 |
| 2016-10 | 0 | $0 | 0 | $0 | 1,000 | $350 |
| 2016-09 | 14,400 | $126,550 | 0 | $0 | 0 | $0 |
| 2016-08 | 0 | $0 | 0 | $0 | 5,328 | $18,648 |
| 2016-05 | 0 | $0 | 0 | $0 | 6,000 | $21,000 |
| 2015-02 | 0 | $0 | 503,150 | $11,069,803 | 0 | $0 |
| 2015-01 | 0 | $0 | 1,996 | $49,700 | 1,996 | $9,780 |
| 2014-12 | 0 | $0 | 59,000 | $1,244,689 | 9,000 | $44,100 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-07-01 | Potter Stephen W (Chief Business Officer) | Sale | 8,070 | .78 | 6,254 |
| 2022-05-27 | Reynolds Gerald Anthony (Chief Accounting Officer) | Sale | 3,994 | .84 | 3,374 |
| 2022-02-18 | Washer Susan B. (President and CEO) | Sale | 9,950 | 2.18 | 21,691 |
| 2022-02-18 | Washer Susan B. (President and CEO) | Option Ex | 120,686 | .35 | 42,240 |
| 2021-11-01 | Washer Susan B. (President and CEO) | Option Ex | 3,877 | 3.50 | 13,569 |
| 2019-12-26 | Inspirational Visions B.v. (10% Owner) | Sale | 81,162 | 5.24 | 425,288 |
| 2019-11-19 | Inspirational Visions B.v. (10% Owner) | Buy | 2,544 | 2.79 | 7,097 |
| 2019-09-18 | Washer Susan B. (President and CEO) | Option Ex | 5,700 | 3.50 | 19,950 |
| 2019-05-28 | Koenig Scott (Director) | Option Ex | 32,018 | .35 | 11,206 |
| 2018-12-14 | Shearman Mark S (Chief Scientific Officer) | Sale | 3,000 | 3.35 | 10,053 |
| 2018-12-14 | Rosen James (Director) | Buy | 1,000 | 3.38 | 3,381 |
| 2018-12-14 | Washer Susan B. (President and CEO) | Buy | 2,380 | 3.34 | 7,949 |
| 2018-12-14 | Aliski William (Director) | Buy | 6,000 | 3.24 | 19,452 |
| 2018-12-14 | Sullivan William A. (Chief Financial Officer) | Buy | 3,000 | 3.33 | 9,990 |
| 2016-11-16 | Magovcevic Ivana (Director) | Buy | 3,000 | 9.62 | 28,875 |
| 2016-11-01 | Chulay Jeffrey D. (VP and Chief Medical Officer) | Sale | 1,000 | 7.05 | 7,052 |
| 2016-10-19 | Chulay Jeffrey D. (VP and Chief Medical Officer) | Option Ex | 1,000 | .35 | 350 |
| 2016-09-22 | Shearman Mark S (Chief Scientific Officer) | Buy | 3,000 | 8.87 | 26,604 |
| 2016-09-20 | Potter Stephen W (See Remarks) | Buy | 400 | 8.69 | 3,476 |
| 2016-09-19 | Bullock Lawrence E (Chief Financial Officer) | Buy | 10,000 | 8.75 | 87,500 |
| 2016-09-16 | Potter Stephen W (See Remarks) | Buy | 1,000 | 8.97 | 8,970 |
| 2016-08-29 | Washer Susan B. (See Remarks) | Option Ex | 5,328 | 3.50 | 18,648 |
| 2016-05-25 | Chulay Jeffrey D. (VP and Chief Medical Officer) | Option Ex | 2,000 | 3.50 | 7,000 |
| 2016-05-11 | Chulay Jeffrey D. (VP and Chief Medical Officer) | Option Ex | 4,000 | 3.50 | 14,000 |
| 2015-02-23 | Glaxosmithkline Plc | Sale | 503,150 | 22.00 | 11,069,803 |
| 2015-01-23 | Menichella Daniel L (V.P. & Chief Business Officer) | Sale | 1,996 | 24.90 | 49,700 |
| 2015-01-23 | Menichella Daniel L (V.P. & Chief Business Officer) | Option Ex | 1,996 | 4.90 | 9,780 |
| 2014-12-22 | Menichella Daniel L (V.P. & Chief Business Officer) | Sale | 9,000 | 20.83 | 187,469 |
| 2014-12-22 | Menichella Daniel L (V.P. & Chief Business Officer) | Option Ex | 9,000 | 4.90 | 44,100 |
| 2014-12-18 | Glaxosmithkline Plc | Sale | 12,000 | 21.01 | 252,132 |
| 2014-12-17 | Glaxosmithkline Plc | Sale | 8,000 | 21.00 | 168,000 |
| 2014-12-12 | Glaxosmithkline Plc | Sale | 7,500 | 21.24 | 159,292 |
| 2014-12-11 | Glaxosmithkline Plc | Sale | 12,500 | 21.28 | 266,037 |
| 2014-12-10 | Glaxosmithkline Plc | Sale | 10,000 | 21.18 | 211,759 |
Insider trading activities including stock purchases, stock sales, and option exercises of AGTC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Applied Genetic Technologies Corp (symbol AGTC, CIK number 1273636) see the Securities and Exchange Commission (SEC) website.